Skip to main content

Advertisement

SpringerLink
Log in

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This work was initiated to extend data on the effect of pharmacogenetics and chemotherapy pharmacokinetics (PK) on clinical outcome in patients with gastrointestinal malignancies.

Methods

We assessed 44 gene polymorphisms in 16 genes (TYMS, MTHFR, GSTP1, GSTM1, GSTT1, DPYD, XRCC1, XRCC3, XPD, ERCC1, RECQ1, RAD54L, ABCB1, ABCC2, ABCG2 and UGT2B7) in 64 patients with metastatic colorectal cancer (CRC) receiving capecitabine/oxaliplatin and 76 patients with advanced gastroesophageal cancer (GEC) receiving epirubicin/cisplatin/capecitabine, respectively. Plasma concentrations of anticancer drugs were measured for up to 24 h, and results were submitted to population PK analysis. We calculated the association between gene polymorphisms, chemotherapy exposure, tumor response, progression-free survival (PFS), overall survival (OS) and chemotherapy-related toxicity using appropriate statistical tests.

Results

Patients with a low clearance of 5FU were at increased risk of neutropenia (P < 0.05) and hand–foot syndrome (P = 0.002). DPYD T85C, T1896C and A2846T mutant variants were associated with diarrhea (P < 0.05) and HFS (P < 0.02), and IVS14+1G>A additionally with diarrhea (P < 0.001). The TYMS 2R/3G, 3C/3G or 3G/3G promoter variants were associated with worse PFS in the CRC (HR = 2.0, P < 0.01) and GEC group (HR = 5.4, P < 0.001) and worse OS in the GEC group (HR = 4.7, P < 0.001). The GSTP1 A313G mutant variant was associated with a higher PFS (HR = 0.55, P = 0.001) and OS (HR = 0.60, P = 0.002) in the CRC group.

Conclusions

Germline polymorphisms of DPYD, TYMS and GSTP1 have a significant effect on toxicity and clinical outcome in patients receiving capecitabine-based chemotherapy for advanced colorectal or gastroesophageal cancer. These data should further be validated in prospective clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clinic 64(1):9–29. doi:10.3322/caac.21208

    Article  Google Scholar 

  2. Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, Gonzalez-Flores E, Aparicio J, Rivera F, Losa F, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors T (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol Off J Am Soc Clin Oncol 25 (27):4224–4230. doi:10.1200/JCO.2006.09.8467

  3. Skof E, Rebersek M, Hlebanja Z, Ocvirk J (2009) Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9:120. doi:10.1186/1471-2407-9-120

    Article  PubMed Central  PubMed  Google Scholar 

  4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United K (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46. doi:10.1056/NEJMoa073149

  5. Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T (2012) Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Ann Hematol 91(4):613–620. doi:10.1007/s00277-011-1343-8

    Article  CAS  PubMed  Google Scholar 

  6. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 25(10):1247–1254. doi:10.1200/JCO.2006.08.1844

    Article  CAS  Google Scholar 

  7. Ruzzo A, Graziano F, Kawakami K, Watanabe G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R, Menichetti ET, Mari D, Testa E, Silva R, Vincenzi B, Giordani P, Cascinu S, Giustini L, Tonini G, Magnani M (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 24(12):1883–1891. doi:10.1200/JCO.2005.04.8322

    Article  CAS  Google Scholar 

  8. Cui YH, Liu TS, Zhuang RY, Gao HJ, Li H (2009) Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer. J Dig Dis 10(2):118–123. doi:10.1111/j.1751-2980.2009.00373.x

    Article  CAS  PubMed  Google Scholar 

  9. Arrazubi V, Suarez J, Guerrero D, Gomez M, Viudez A, Arias F, Balen E, Vera R (2013) Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Colorect Dis Off J Assoc Coloproctol GB Irel 15(4):428–435. doi:10.1111/codi.12009

    CAS  Google Scholar 

  10. Castillo-Fernandez O, Santibanez M, Bauza A, Calderillo G, Castro C, Herrera R, Serrano A, Arrieta O, Herrera LA (2010) Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid. Arch Med Res 41(6):430–435. doi:10.1016/j.arcmed.2010.08.011

    Article  CAS  PubMed  Google Scholar 

  11. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 17(10):3455–3468. doi:10.1158/1078-0432.CCR-10-2209

    Article  CAS  Google Scholar 

  12. Saif MW (2013) Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genom Proteomics 10(2):89–92

    CAS  Google Scholar 

  13. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM (2013) Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 108(12):2505–2515. doi:10.1038/bjc.2013.262

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiader CR (2015) Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer J Int du Cancer 136(3):730–739. doi:10.1002/ijc.29025

    CAS  Google Scholar 

  15. Li Q, Liu Y, Zhang HM, Huang YP, Wang TY, Li DS, Sun HZ (2014) Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract 2014:827989. doi:10.1155/2014/827989

    PubMed Central  PubMed  Google Scholar 

  16. Huang D, Zhou Y (2014) Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed Rep 2(4):452–462. doi:10.3892/br.2014.282

    PubMed Central  CAS  PubMed  Google Scholar 

  17. Qin Q, Zhang C, Yang X, Zhu H, Yang B, Cai J, Cheng H, Ma J, Lu J, Zhan L, Liu J, Liu Z, Xu L, Sun X (2013) Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies. PLoS ONE 8(11):e79864. doi:10.1371/journal.pone.0079864

    Article  PubMed Central  PubMed  Google Scholar 

  18. Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS (2010) Influence of GSTP1 I105 V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101(2):530–535. doi:10.1111/j.1349-7006.2009.01418.x

    Article  CAS  PubMed  Google Scholar 

  19. Lv H, Han T, Shi X, Yao Y, Yao Y, Qiu W, Yue L, Liang J (2014) Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med Oncol 31(8):86. doi:10.1007/s12032-014-0086-5

    Article  PubMed  Google Scholar 

  20. Brouwers EE, Tibben MM, Joerger M, van Tellingen O, Rosing H, Schellens JH, Beijnen JH (2005) Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Anal Bioanal Chem 382(7):1484–1490. doi:10.1007/s00216-005-3302-5

    Article  CAS  PubMed  Google Scholar 

  21. van Asperen J, van Tellingen O, Beijnen JH (1998) Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 712(1–2):129–143

    Article  PubMed  Google Scholar 

  22. Vainchtein LD, Rosing H, Schellens JH, Beijnen JH (2010) A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed Chromatogr BMC 24(4):374–386. doi:10.1002/bmc.1302

    CAS  Google Scholar 

  23. Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F, Cerny T, Schellens JH, Gillessen S (2014) Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 73(1):113–124. doi:10.1007/s00280-013-2327-2

    Article  CAS  PubMed  Google Scholar 

  24. Guichard SM, Macpherson JS, Mayer I, Reid E, Muir M, Dodds M, Alexander S, Jodrell DI (2008) Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer 44(2):310–317. doi:10.1016/j.ejca.2007.10.023

    Article  CAS  PubMed  Google Scholar 

  25. Suenaga M, Fuse N, Yamaguchi T, Yamanaka Y, Motomura S, Matsumoto H, Hamamoto Y, Mizunuma N, Doi T, Hatake K, Iwasaki J, Ohtsu A (2014) Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. J Clin Pharmacol. doi:10.1002/jcph.246

  26. Kawakami K, Omura K, Kanehira E, Watanabe Y (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19(4B):3249–3252

    CAS  PubMed  Google Scholar 

  27. Kawakami K, Watanabe G (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63(18):6004–6007

    CAS  PubMed  Google Scholar 

  28. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ (2002) Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17(1):46–49

    Article  PubMed  Google Scholar 

  29. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1(1):65–70

    Article  CAS  PubMed  Google Scholar 

  30. Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94(2):281–286. doi:10.1038/sj.bjc.6602891

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, Catalano V, Bisonni R, Arduini F, Bearzi I, Cascinu S, Muretto P, Perrone G, Rabitti C, Giustini L, Tonini G, Pizzagalli F, Magnani M (2005) Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Re Off J Am Assoc Cancer Res 11(10):3778–3783. doi:10.1158/1078-0432.CCR-04-2428

    Article  CAS  Google Scholar 

  32. Ye F, Liu Z, Tan A, Liao M, Mo Z, Yang X (2013) XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemother Pharmacol 71(3):733–740. doi:10.1007/s00280-012-2067-8

    Article  CAS  PubMed  Google Scholar 

  33. van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ, Maropoulos GD, Hein G, Kalhoff H, Kirk JM, Baaske H, Aukett A, Duley JA, Ward KP, Lindqvist Y, van Gennip AH (2002) Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 364(Pt 1):157–163

    PubMed Central  PubMed  Google Scholar 

  34. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 94(6):640–645. doi:10.1038/clpt.2013.172

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Henin E, You B, VanCutsem E, Hoff PM, Cassidy J, Twelves C, Zuideveld KP, Sirzen F, Dartois C, Freyer G, Tod M, Girard P (2009) A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther 85(4):418–425. doi:10.1038/clpt.2008.220

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a fellowship grant of the European Society of Medical Oncology Grant (ESMO), a research grant of the Union International Contre le Cancer Grant (UICC) and a Research Grant from the Swiss National Science Foundation (SNF) (PBBSB-102331).

Conflict of interest

No potential conflicts of interest were disclosed by the authors.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Cantonal Hospital, Rorschacherstr. 95, 9007, St. Gallen, Switzerland

    M. Joerger, M. Zueger & T. D. Cerny

  2. Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    A. D. R. Huitema, L. Vainchtein, H. Rosing & J. H. Beijnen

  3. Department of Gastroenterology, Antoni Van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    H. Boot & A. Cats

  4. Department of Molecular Biology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    V. D. Doodeman & P. H. M. Smits

  5. Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands

    I. Meijerman, J. H. Beijnen & J. H. M. Schellens

  6. Division of Clinical Pharmacology and Toxicology, University Hospital, Basel, Switzerland

    M. Zueger

  7. Department of Molecular Pathology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    D. Meulendijks

  8. Department of Clinical Pharmacology, Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands

    J. H. Beijnen & J. H. M. Schellens

Authors
  1. M. Joerger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. D. R. Huitema
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Boot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Cats
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. D. Doodeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. H. M. Smits
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Vainchtein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Rosing
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. Meijerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Zueger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D. Meulendijks
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. T. D. Cerny
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J. H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. H. M. Schellens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Joerger.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 117 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joerger, M., Huitema, A.D.R., Boot, H. et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 75, 763–772 (2015). https://doi.org/10.1007/s00280-015-2698-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2698-7

Keywords

Search

Navigation